Solid guidance hit, margins at low end — market votes "show me the 18–20%"

The earnings landed squarely on guidance — revenue +11.3%, PAT +15.8%, both within the band of 10–15%. Domestic API surged 27%, gross margin expanded 210 basis points on stable pricing, and the company held the line on its FY27 outlook. On paper, a solid quarter. But the market has other ideas. The stock fell 4.45% on day 1 of the announcement, and by day 5 it was down 17.31% — a vote that the headline covers a deeper concern.

Revenue broke down as: Domestic API ₹92.3 Cr (up 27%), Export API ₹50.1 Cr (lagging due to geopolitical headwinds), and Formulation ₹23.3 Cr. The surge in domestic API — ascorbic acid, Vitamin C, and early Semaglutide prep — was the growth engine. The weakness in export (which sits at 30% of API mix) was offset, but not fully absorbed. The margin story: Gross profit swelled 210 basis points to 48.3%, signalling that pricing held despite volatile oil costs and geopolitical churn. But EBITDA came in at ₹29.6 Cr, yielding a 17.8% margin — the low end of management's 18–20% guidance band for FY27–28. The gap came from operating expenses and working capital drag (more below). The company squeezed out a 70 basis point year-on-year margin lift, but it sits below where management said it would land.

Receivables tightened from 145 days to 131 days year-on-year, but the company's target is 110–120 days. Management cited working capital as a priority and expects further improvement, but the timeline is vague. Inventory remains elevated due to geopolitical hedging in Q4 — the company deliberately ordered stock ahead of supply chain risk — and CFO said it "will get better" without quantifying when. This drag explains some of the EBITDA miss vs. guidance, and until receivables stabilize closer to the 110–120 day target, it will remain a headwind to cash conversion.

This was the company's first formal earnings call. Three pieces of new guidance were issued: 1. FY27 revenue and PAT growth both 10–15%. This set the band against which Q1 was judged (and met). 2. EBITDA margin 18–20% for FY27–28. Q1 came in at 17.8%, below this range, but within execution tolerance. 3. Long-term target of ₹900–1000 Cr revenue in 2–3 years. This is roughly 5.5–6× annualized Q1 run-rate (₹662 Cr), driven by peptide ramp (₹200–300 Cr at peak), CDMO, formulation mix shift, and oncology API. No prior guidance exists to compare against.

The stock opened at ₹386.55 before the result (July 20). It fell 4.45% on day 1, but the decline did not fade — by day 3 it was down 17.81%, and by day 5 it settled down 17.31%. This is not a headline-disappointment pop-and-fade; it's a sustained repricing. The market is asking: if this is a "solid quarter" and guidance is on track, why is the stock now 31% off its all-time high of ₹490, trading at ₹336.45, below its 50-day moving average (₹342.57)? RSI sits at 47.6 (neutral territory), and volume is normal — no panic, but no conviction either. FII ownership edged up 0.8 percentage points to 1.98%, but DII was flat (2.91%), suggesting no broad-based institutional enthusiasm. No notable insider selling was flagged in the bulk block deals; the large trades on Jun 29 were algorithmic/trading desk activity.

Hold (confidence 6/10). Q1 delivered solidly on the headline numbers, but the market's 31% retreat from all-time high reflects a real repricing: investors are discounting the execution risk on the 2–3 year peptide ramp, regulatory timelines, and margin recovery. Management is credible and the FY27 guidance is achievable, but believers in the ₹900–1000 Cr story need patience and regulatory wins. The stock's drawdown has priced in some caution; there is no margin of safety yet for new longs.